Related references
Note: Only part of the references are listed.Pharmacokinetic interactions of almorexant with midazolam and simvastatin, two CYP3A4 model substrates, in healthy male subjects
Matthias Hoch et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2013)
Dual orexin receptor antagonism by almorexant does not potentiate impairing effects of alcohol in humans
Matthias Hoch et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2013)
Hydrolytic instability of the important orexin 1 receptor antagonist SB-334867: Possible confounding effects on in vivo and in vitro studies
Charles J. McElhinny et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2012)
Discovery of [(2R,5R)-5-{[(5-Fluoropyridin-2-yl)oxy]methyl}-2-methylpiperidin-1-yl][5-methyl-2-(pyrimidin-2-yl)phenyl]methanone (MK-6096): A Dual Orexin Receptor Antagonist with Potent Sleep-Promoting Properties
Paul J. Coleman et al.
CHEMMEDCHEM (2012)
Orexin Receptor Antagonism, a New Sleep-Enabling Paradigm: A Proof-of-Concept Clinical Trial
P. Hoever et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2012)
Functional and binding kinetic studies make a distinction between OX1 and OX2 orexin receptor antagonists
Stefania Faedo et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2012)
Phase I studies on the safety, tolerability, pharmacokinetics and pharmacodynamics of SB-649868, a novel dual orexin receptor antagonist
Paolo Bettica et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2012)
Orexin receptor antagonism: an ascending multiple-dose study with almorexant
Petra Hoever et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2012)
Orexin receptor antagonism for treatment of insomnia A randomized clinical trial of suvorexant
W. Joseph Herring et al.
NEUROLOGY (2012)
Pharmacological characterization of MK-6096-A dual orexin receptor antagonist for insomnia
Christopher J. Winrow et al.
NEUROPHARMACOLOGY (2012)
Differential Effects of a Dual Orexin Receptor Antagonist (SB-649868) and Zolpidem on Sleep Initiation and Consolidation, SWS, REM Sleep, and EEG Power Spectra in a Model of Situational Insomnia
Paolo Bettica et al.
NEUROPSYCHOPHARMACOLOGY (2012)
Absolute Oral Bioavailability of Almorexant, a Dual Orexin Receptor Antagonist, in Healthy Human Subjects
Matthias Hoch et al.
PHARMACOLOGY (2012)
International Union of Basic and Clinical Pharmacology. LXXXVI. Orexin Receptor Function, Nomenclature and Pharmacology
Anthony L. Gotter et al.
PHARMACOLOGICAL REVIEWS (2012)
Orexin Receptors: Pharmacology and Therapeutic Opportunities
Thomas E. Scammell et al.
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 51, 2011 (2011)
Discovery process and pharmacological characterization of a novel dual orexin 1 and orexin 2 receptor antagonist useful for treatment of sleep disorders
Romano Di Fabio et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2011)
Disposition and Metabolism of [14C]SB-649868, an Orexin 1 and 2 Receptor Antagonist, in Humans
Cecilia Renzulli et al.
DRUG METABOLISM AND DISPOSITION (2011)
Food Effect and Biocomparison of Two Formulations of the Dual Orexin Receptor Antagonist Almorexant in Healthy Male Subjects
Matthias Hoch et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2011)
Preface to the Special Issue Novel Pharmaconeurogenetic Approaches Arising from Progress in Translational Genetics
John J. Renger et al.
JOURNAL OF NEUROGENETICS (2011)
Promotion of Sleep by Suvorexant--A Novel Dual Orexin Receptor Antagonist
Christopher J. Winrow et al.
JOURNAL OF NEUROGENETICS (2011)
Differential Effects of the Dual Orexin Receptor Antagonist Almorexant and the GABAA-α1 Receptor Modulator Zolpidem, Alone or Combined with Ethanol, on Motor Performance in the Rat
Michel A. Steiner et al.
NEUROPSYCHOPHARMACOLOGY (2011)
Functional Magnetic Resonance Imaging Reveals Different Neural Substrates for the Effects of Orexin-1 and Orexin-2 Receptor Antagonists
Alessandro Gozzi et al.
PLOS ONE (2011)
Pharmacokinetics and Tolerability of Almorexant in Japanese and Caucasian Healthy Male Subjects
Matthias Hoch et al.
PHARMACOLOGY (2011)
Orexin receptor antagonists: a review of promising compounds patented since 2006
Paul J. Coleman et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2010)
Discovery of the Dual Orexin Receptor Antagonist [(7R)-4-(5-Chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone (MK-4305) for the Treatment of Insomnia
Christopher D. Cox et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
Antagonism of rat orexin receptors by almorexant attenuates central chemoreception in wakefulness in the active period of the diurnal cycle
Aihua Li et al.
JOURNAL OF PHYSIOLOGY-LONDON (2010)
British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders
S. J. Wilson et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2010)
Biochemical and behavioural characterization of EMPA, a novel high-affinity, selective antagonist for the OX2 receptor
P. Malherbe et al.
BRITISH JOURNAL OF PHARMACOLOGY (2009)
Blockade of Orexin-1 Receptors Attenuates Orexin-2 Receptor Antagonism-Induced Sleep Promotion in the Rat
Christine Dugovic et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2009)
Proline bis-amides as potent dual orexin receptor antagonists
Jeffrey M. Bergman et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2008)
Effects of prolonged-release melatonin, zolpidem, and their combination on psychomotor functions, memory recall, and driving skills in healthy middle aged and elderly volunteers
S. Otmani et al.
HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL (2008)
Promotion of sleep by targeting the orexin system in rats, dogs and humans
Catherine Brisbare-Roch et al.
NATURE MEDICINE (2007)
A double-blind, placebo-controlled investigation of the residual psychomotor and cognitive effects of zolpidem-MR in healthy elderly volunteers
Ian Hindmarch et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2006)
Concomitant loss of dynorphin, NARP, and orexin in narcolepsy
A Crocker et al.
NEUROLOGY (2005)
Novel substituted 4-phenyl-[1,3]dioxanes:: potent and selective orexin receptor 2 (OX2R) antagonists
LC McAtee et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2004)
Characterisation of the binding of [H-3]-SB-674042, a novel nonpeptide antagonist, to the human orexin-1 receptor
CJ Langmead et al.
BRITISH JOURNAL OF PHARMACOLOGY (2004)
Expression of a poly-glutamine-ataxin-3 transgene in orexin neurons induces narcolepsy-cataplexy in the rat
CT Beuckmann et al.
JOURNAL OF NEUROSCIENCE (2004)
The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias
E Mignot et al.
ARCHIVES OF NEUROLOGY (2002)
1,3-Biarylureas as selective non-peptide antagonists of the orexin-1 receptor
RA Porter et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2001)
Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity
J Hara et al.
NEURON (2001)
SB-334867-A: the first selective orexin-1 receptor antagonist
D Smart et al.
BRITISH JOURNAL OF PHARMACOLOGY (2001)
A selective orexin-1 receptor antagonist reduces food consumption in male and female rats
AC Haynes et al.
REGULATORY PEPTIDES (2000)
Diurnal variation in orexin A immunoreactivity and prepro-orexin mRNA in the rat central nervous system
S Taheri et al.
NEUROSCIENCE LETTERS (2000)
A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains
C Peyron et al.
NATURE MEDICINE (2000)
Hypocretin (orexin) deficiency in human narcolepsy
S Nishino et al.
LANCET (2000)
Share Paper
